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Introduction: Undifferentiated pleomorphic sarcoma is defined as a pleomorphic high-grade sarcoma whose line
of differentiation cannot be determined. These tumors constitute less than 5% of all sarcomas in adults. Cardiac
neoplasms are rare, and most are metastatic in origin. More than one-third of cardiac metastases originate from
lung cancer. Symptoms of cardiac neoplasms usually appear late in the course of the disease and are often ignored
because of the more severe effects of the primary malignancy or its therapy. We present the case of a patient with
undifferentiated pleomorphic sarcoma of the lung presenting with symptomatic right-heart failure secondary to
cardiac metastasis. The purpose of this report is to present this unusual case.
Case presentation: Our patient was a 59-year-old Chinese woman with symptomatic metastasis of an undifferentiated
pleomorphic sarcoma of the lung to the right ventricle. She had a history of a stage IV, pulmonary, undifferentiated
pleomorphic sarcoma that had been successfully treated with chemotherapy and radiotherapy 4 years ago. A complete
response was obtained, and she was in remission until the cardiac metastasis. She underwent surgical excision of the
cardiac mass because it caused dyspnea and posed a high risk of sudden death, pulmonary embolism or tricuspid
obstruction. Histopathological and immunohistochemical examinations of the surgical specimen established the diagnosis
of undifferentiated pleomorphic sarcoma and confirmed that the cardiac tumor was a metastasis from the lung.
Conclusions: In patients who have known metastatic neoplasms and present with cardiac manifestations, whether
detected during history taking or physical examination, the clinician should be alert to the possibility of cardiac metastases.
In patients with cardiac metastases, the therapeutic alternatives are limited to palliative treatment of symptoms and
chemotherapy. In some patients, surgery can be used to relieve symptoms. We have reported the first case of symptomatic
cardiac metastases from an undifferentiated pleomorphic sarcoma of the lung. Our patient underwent surgical resection,
and her symptoms improved significantly. This case is unique because it is the only reported case of undifferentiated
pleomorphic sarcoma of the lung which metastasized to the heart, and in which symptomatic improvement was
effectively obtained with surgical resection.
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Undifferentiated pleomorphic sarcoma is defined as a pleo-
morphic high-grade sarcoma whose line of differentiation
cannot be determined. These tumors constitute less than
5% of all sarcomas in adults [1]. From a clinical viewpoint,
undifferentiated pleomorphic sarcomas are deeply located* Correspondence: xuguodong5306750@gmail.com
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reproduction in any medium, provided the ortumors that show progressive and rapid growth. The mean
5-year survival rate ranges from 50% to 60% [2].
Cardiac neoplasms are rare, and most are metastatic
in origin. Cardiac metastases are found at autopsy in 6%
to 20% of patients with malignant neoplasms [3]. More
than one-third (36%) of cardiac metastases originate
from lung cancer. Non-solid primary malignancies such
as leukemia, lymphoma and Kaposi sarcoma account for
20% of cardiac metastases, breast carcinoma for 7% and
esophageal carcinoma for 6% [4].This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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the course of the disease and are often ignored because
of the more severe effects of the primary malignant dis-
order or its therapy. Consequently, cardiac neoplasms,
especially metastatic ones, are often not discovered until
autopsy.
We present the case of a patient with undifferentiated
pleomorphic sarcoma of the lung presenting with symp-
tomatic right-heart failure secondary to cardiac metasta-
sis. The purpose of this report is to present this unusual
case.
Case presentation
A 59-year-old Chinese woman was referred to our hospital
11 months ago because she had had dyspnea for more than
1 month. She had a history of stage IV lung cancer that was
located in the left upper lobe. Transthoracic echocardiog-
raphy revealed no right ventricular tumor at the time the
original left lung cancer was diagnosed (Figure 1). The pa-
tient was diagnosed by fiberoptic bronchoscopic biopsy. Im-
munohistochemical analysis demonstrated that the tumor
cells were strongly positive for vimentin and CD68, and
moderately positive for Ki-67(+). Focal staining for actin and
desmin was also observed, but S-100, CD34(−), CK(pan),
CAM5.2 and epithelial membrane antigen (EMA) were all
negative. Histopathological and immunohistochemical
examinations confirmed a diagnosis of undifferentiated
pleomorphic sarcoma 4 years ago. She had successfully
undergone multiple sessions of radiotherapy and chemo-
therapy, and no recurrence was observed during follow-up.
On a physical examination, her blood pressure was
110/70mmHg, and her pulse rate was 110 beats per mi-
nute and regular. A cardiac examination revealed a right
ventricular impulse; a systolic thrill was palpable at theFigure 1 Transthoracic echocardiographic scan (parasternal
short-axis view of aortic root) 4 years ago. No tumor was
revealed in the right ventricle.left sternal border, and a grade III/IV systolic ejection
murmur was audible in the same region. On ausculta-
tion, her chest was clear.
Contrast-enhanced computed tomography (CT) showed a
large mass measuring 5cm × 6cm, filling defects in the main
pulmonary artery and right ventricle and hydropericardium
(Figure 2). No abnormal findings were seen in the lung.
Transthoracic echocardiography revealed enlargement of
the right ventricle, hydropericardium and a tumor measur-
ing approximately 5cm × 5cm and extending from the right
ventricle to the pulmonary valve (Figure 3). The liver, spleen,
pancreas, and kidneys appeared normal. The patient had no
evidence of tumor recurrence in the left lung. Her electro-
cardiogram showed sinus rhythm with no significant ST-T
abnormalities. Serum levels of the tumor markers alpha-
fetoprotein, carcinoembryonic antigen, carcinoma antigen
(CA)-125 and CA 19–9 were not elevated.
After considering the extent of the patient’s disease,
we deemed that an operation was the best alternative.
The tumor in the right ventricle and main pulmonary
artery was surgically resected; it measured 6cm × 5cm
(Figure 4). The postoperative course was uneventful, and
she was discharged on day 13 after the surgery. Her dys-
pnea was significantly relieved postoperatively. Histopatho-
logical examination of the resected specimen indicated a
diagnosis of undifferentiated sarcoma (Figure 5). Immuno-
histochemical analysis demonstrated that the tumor cells
were strongly positive for vimentin and CD68, and moder-
ately positive for Ki-67(+). Focal staining for actin and
desmin was also observed, but S-100, CD34(−), CK(pan),
CAM5.2 and EMA were all negative.
When seen at the last follow-up 2 months ago, our pa-
tient was in complete remission, with no evidence of
tumor recurrence on CT and echocardiography.
Discussion
We have described the first case of cardiac metastasis
from an undifferentiated pleomorphic sarcoma of the
lung. Immunohistochemistry may be useful to distin-
guish pulmonary undifferentiated pleomorphic sarcomas
from non-mesenchymal malignant tumors and to delin-
eate the level of differentiation of the sarcomas [5]. The
limited data available on undifferentiated pleomorphic
sarcomas indicate that this neoplasm has an aggressive
clinical course, and a high incidence of recurrence and
metastasis. Surgical resection is the primary therapeutic
modality of this sarcoma. If the tumor is at an advanced
stage, combination chemotherapy or radiotherapy may
be used as a palliative approach. The overall 5-year sur-
vival of patients with undifferentiated pleomorphic sar-
coma is approximately 50% [6]. Our patient was
diagnosed with a stage IV, undifferentiated pleomorphic
sarcoma of the lung and was treated with multiple cycles
of chemotherapy and radiotherapy 4 years ago. This
Figure 2 Preoperative, contrast-enhanced, computed tomographic scan of the chest. A large mass measuring 5cm × 6cm, filling defects in
the main pulmonary artery and right ventricle and hydropericardium can be seen (arrows).
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tumor recurrence did not occur.
Cardiac involvement is not uncommon in lung cancer,
and is detected in approximately 25% of autopsy cases
[7,8]. In a study by Tamura et al., cardiac involvement
was found at autopsy in 23 of 78 patients with lung can-
cer [9]. Despite the significant mortality and morbidityFigure 3 Preoperative, transthoracic echocardiographic scan
(parasternal short-axis view of aortic root). A tumor measuring
approximately 5cm × 5cm and extending from the right ventricle to
the pulmonary valve can be seen (arrow).with which it is associated, cardiac metastasis is usually
diagnosed during autopsy. Most cardiac metastases are
asymptomatic [10]. Only 10% of patients with cardiac
metastasis have symptoms, which are typically related to
cardiac function. The clinical presentation variesFigure 4 Intraoperative specimen. The partially resected tumor
obstructed the right ventricular and main pulmonary artery.
Figure 5 Photomicrograph of resected specimen.
Histopathological examination of the specimen shows that the
tumor is an undifferentiated pleomorphic sarcoma (hematoxylin and
eosin stain; original magnification, ×100).
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involvement. The small number of reported cases of
symptomatic cardiac metastasis attests to the rarity of
metastatic lesions that are large enough to cause right
ventricular outflow tract obstruction. Our patient
presented with dyspnea because of right ventricular out-
flow tract obstruction. The main differences between
primary pulmonary artery sarcoma and metastatic lung
disease in the same area is that metastatic lung disease
has a history of lung cancer and histopathological and
immunohistochemical examinations should be done ac-
cordingly with the primary lung cancer. Histopatho-
logical and immunohistochemical examinations of the
surgical specimen in our patient clearly showed that the
cardiac tumor was a metastasis from the lung cancer.
Although such cardiac metastases are not uncommon at
autopsy, this is the first reported case of a cardiac metas-
tasis from an undifferentiated pleomorphic sarcoma of
the lung that was diagnosed in a living patient and was
successfully treated with surgery.
Since cardiac metastases are often incurable, surgical
resection is not an optimal option for patients with
metastatic involvement of the heart. Systemic chemo-
therapy is usually the most beneficial treatment. Never-
theless, metastatic cardiac involvement poses other
problems. Resection of malignant sarcomas is usually
only palliative. In cases where the metastasis results in
cardiac tamponade or valve obstruction, palliative sur-
gery is often used to relieve symptoms if the primary
tumor has been resected in toto, and the patient appears
to have a good prognosis. Palliative radiotherapy to the
heart is rarely helpful or indicated to relieve symptoms.
In patients with unresectable malignant tumor, palliative
surgery may be used, but without great expectation of suc-
cessful results. Bakaeen et al. [11] reported that the mediansurvival time of patients with malignant cardiac tumors was
9.6 months. Burke et al. [12] reported that the average and
median survival in 75 patients with primary malignant car-
diac sarcoma was 11 months and 6 months, respectively.
Survival depends on the extent of resection of the sar-
comas because of their high potential for recurrence and
metastasis. Mean survival after surgical excision has
been documented to be 9 to 10 months; a significant
predictor of long-term mortality is the presence of New
York Heart Association Class III and IV symptoms [11].
The role of adjuvant chemotherapy and radiotherapy is
unclear. Given the limited data and the lack of random-
ized trials, complete surgical resection is currently the
only factor that influences survival [13]. In our patient,
wide local excision of the recurrent mass was performed,
without adjuvant chemotherapy and radiation.
Surgical excision was selected not only because she
had had a good outcome after undergoing chemotherapy
and radiotherapy 4 years ago but also to prevent intra-
cardiac blood flow obstruction and congestive heart fail-
ure. Six months after the surgery, she had recovered
well, with no evidence of tumor recurrence on CT and
echocardiography.
Conclusions
Cardiac metastasis from lung cancer is rare and is mainly
found at autopsy as an incidental, non-symptomatic find-
ing. In patients who have known metastatic neoplasms
and who present with cardiac manifestations, whether
detected on history taking or physical examination, the
clinician should be alert to the possibility of cardiac me-
tastases. We have reported the first case of symptomatic
cardiac metastases from an undifferentiated pleomorphic
sarcoma of the lung.
In patients with cardiac metastases, the therapeutic al-
ternatives are limited to palliative treatment of symp-
toms and chemotherapy. In some patients, surgery can
be used to relieve symptoms. Our patient underwent
surgical resection, and her symptoms improved signifi-
cantly. However, treatment of all the metastatic cardiac
tumors provides only palliation. Mean survival of af-
fected patients is 3 months to 1 year for metastatic car-
diac tumors [14]. The patient will be examined every 3
months by echocardiography in the next 2 years.
This case is unique because it is the only reported case
of undifferentiated pleomorphic sarcoma of the lung
which metastasized to the heart, and in which symptom-
atic improvement was obtained after surgical resection.
Consent
Written informed consent was obtained from the patient
for the publication of this case report and the accompany-
ing images. A copy of the written consent is available for
review by the Editor-in-Chief of this journal.
Xu et al. Journal of Medical Case Reports 2013, 7:165 Page 5 of 5
http://www.jmedicalcasereports.com/content/7/1/165Competing interests
The authors declare that they have no competing interests in the
preparation of this article.
Authors’ contributions
GX drafted the manuscript. GX and XS treated the patient. GS and XS
participated in the design of the study. All authors read and approved the
final manuscript.
Received: 15 January 2013 Accepted: 2 May 2013
Published: 27 June 2013
References
1. Fletcher CD: The evolving classification of soft tissue tumours: an update
based on the new WHO classification. Histopathology 2006, 48:3–12.
2. Fletcher CDM, Unni KK, Mertens F: World Health Organization classification of
tumours. Pathology and genetics of tumours of soft tissues and bone. Lyon,
France: IARC Press; 2002:120–122.
3. Pinho T, Rodrigues-Pereira P, Araújo V, Oliveira NP, Macedo F, Graça A,
Maciel MJ: Cardiac metastasis of melanoma as first manifestation of
disease. Rev Port Cardiol 2009, 5:633–639.
4. Chiles C, Woodard P, Gutierrez F, Link K: Metastatic involvement of the heart
and pericardium: CT and MR Imaging. Radiographics 2001, 21:439–449.
5. Al-Nafussi A: Spindle cell tumours of the breast: practical approach to
diagnosis. Histopathology 1999, 35:1–13.
6. Zelger B, Burgdorf WH: Fibrohistiocytic tumors. In Skin Cancer. 1st edition.
Edited by Nouri K. New York: McGraw-Hill; 2007:205–207.
7. Kadappu KK, Rajaratnam R, Kachwalla H, Nguyen PD: Lung cancer
mimicking left atrial mass. Postgrad Med J 2008, 84(993):386–387.
8. Bussani R, De-Giorgio F, Abbate A, Silvestri F: Cardiac metastases. J Clin
Pathol 2007, 60(1):27–34.
9. Tamura A, Mastubara O, Yoshimura N, Kasuga T, Akagawa S, Aoki N: Cardiac
metastasis of lung cancer – a study of metastatic pathways and clinical
manifestations. Cancer 1992, 70(2):437–442.
10. Morais VD, Dalbem F, Borges K, Restelli K: Right ventricular tumor in a
patient with melanoma. Arg Bras Cardiol 2008, 91(3):e29–e32. e21–24.
11. Bakaeen FG, Chir B, Reardon MJ, Coselli JS, Miller CC, Howell JF, Lawrie GM,
Espada R, Ramchandani MK, Noon GP, Weilbaecher DG, DeBakey ME: Surgical
outcome in 85 patients with primary cardiac tumors. Am J Surg 2003,
186:641–647.
12. Burke AP, Cowan D, Virmani R: Primary sarcomas of heart. Cancer 1992,
84:387–395.
13. Llombart-Cussac A, Pivot X, Contesso G, Rhor-Alvarado A, Delord JP,
Spielmann M, Tursz T, Le Cesne A: Adjuvant chemotherapy for primary
cardiac sarcomas: the IGR experience. Br J Cancer 1998, 78:1624–1628.
14. Grebenc ML, Rosado de Christenson ML, Burke AP: Primary cardiac and
pericardial neoplasms: radiologic-pathologic correlation. Radiographics 2000,
20:1073–1103.
doi:10.1186/1752-1947-7-165
Cite this article as: Xu et al.: An unusual case of metastasis of a
pulmonary undifferentiated pleomorphic sarcoma to the right ventricle:
a case report. Journal of Medical Case Reports 2013 7:165.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
